[vc_row type=”vc_default” full_width_row=”true” bg_type=”bg_color” bg_override=”full” bg_color_value=”#f4f4f4″ css=”.vc_custom_1491338692434{margin-top: -70px !important;}”][vc_column][vc_custom_heading text=”PARTNER CCCR” font_container=”tag:h1|text_align:left|color:%23232323″ use_theme_fonts=”yes”][vc_custom_heading text=”P.I. TOIVO MAIMETS” font_container=”tag:h2|text_align:left|color:%23606060″ use_theme_fonts=”yes”][vc_custom_heading text=”COMPETENCE CENTRE OF CANCER RESEARCH” font_container=”tag:h4|text_align:left|color:%238e8e8e” use_theme_fonts=”yes”][/vc_column][/vc_row][vc_row][vc_column width=”1/6″][vc_empty_space height=”10px”][vc_single_image image=”141″ img_size=”medium” onclick=”custom_link” img_link_target=”_blank” image_hovers=”false” link=”http://www.vtak.ee/en”][/vc_column][vc_column width=”2/3″][vc_column_text]

The Competence Centre for Cancer Research CCCR is a research and development institution founded in 2005 with the aim to improve the quality of cancer therapy by developing and implementing new diagnostic platforms and offering the pharmaceutical industry new drug candidates. It is certified by the Estonian Ministry of Education and Science. CCCR brings together the top Estonian public institutions and private companies with competences in cancer research.

Toivo Maimets, PhD is Professor of Cell Biology at the University of Tartu. His group presently studies the molecular mechanisms governing cell developmental potency and their role in human tumorigenesis. He is also developing methods for screening low-molecular weight compounds to modulate protein-protein interactions in vivo and use this to design new anti-tumor drugs. His group will collaborate in patients recruitment and biostatistical analysis.

[/vc_column_text][/vc_column][vc_column width=”1/6″][vc_single_image image=”247″ img_size=”full” alignment=”center” image_hovers=”false”][/vc_column][/vc_row][vc_row][vc_column]


1) Kallas, A., et al (2011). Nocodazole treatment decreases expression of pluripotency markers Nanog and Oct4 in human embryonic stem cells. PLoS One 2011 Apr 29;6(4):e19114.

2) Kadaja-Saarepuu, L., et al., (2012). Tumor suppressor p53 down-regulates expression of human leukocyte marker CD43 in non-hematopoietic tumor cells. International Journal of Oncology, 40(2), 567 – 576.

3) Balikova A, et al., Leukocyte marker CD43 promotes cell growth in co-operation with β-catenin in non-hematopoietic cancer cells. Int J Oncol. 2012 Jul;41 (1):299-309.

4) Kallas A., et al., (2014). Assessment of the potential of CDK2 inhibitor NU6140 to influence the expression of pluripotency markers NANOG, OCT4 and SOX2 in 2102Ep and H9 cells. International Journal of Cell Biology, Article ID 280638, doi:10.1155/2014/280638,1 – 16.

5) Pook M. et al., (2015). Changes in laminin expression pattern during early differentiation of human embryonic stem cells. PloS ONE, Sep 17;10(9):e0138346.